A phase Ib MAD trial of GRI-0803
Latest Information Update: 17 May 2024
At a glance
- Drugs GRI 0803 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors GRI Bio
Most Recent Events
- 13 May 2024 According to a GRI Bio media release, the company expects to complete IND-enabling studies and File IND and launch Phase 1a/b in Q3 2024
- 29 May 2023 New trial record
- 22 May 2023 According to a GRI Bio media release, the company expects to complete IND-enabling studies in Q1 2024 and file an IND in 1H 2024. Topline data from this study expected in Q4 2024.